20 completed, 10 active not recruiting, 6 terminated, 6 unknown. 48 Phase 3, 3 Phase 2.
By phase and status
Follow Velcade: new trials by email Literature Review of Velcade trials Research Report on Velcade
Trials (filtered) newest first · largest first
All 48 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma Phase 2 / Phase 3 Not yet recruiting 1708 2026-08-28 2026-07-30
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) AZD0120, Daratumumab, Carfilzomib - Relapsed Refractory Multiple Myeloma Phase 3 Recruiting 508 2026-02-23 2026-09-29
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection - AL Amyloidosis Phase 3 Recruiting 338 2024-07-01 2026-05-06
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide Talquetamab, Pomalidomide, Teclistamab - Multiple Myeloma Phase 3 Active not recruiting 838 2024-01-22 2026-11-03
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Plasma Cell Myeloma Phase 3 Recruiting 510 2023-10-12 2026-06-10
CURATE.AI Optimized Modulation for Multiple Myeloma Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma Phase 2 / Phase 3 Unknown 20 2023-09-10 2023-09-06
Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma Isatuximab, Lenalidomide, Bortezomib - Multiple Myeloma Phase 3 Completed 514 2023-04-14 2026-02-18
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) mezigdomide, Pomalidomide, Bortezomib - Relapsed or Refractory Multiple Myeloma Phase 3 Recruiting 810 2022-09-20 2026-10-30
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma Phase 3 Recruiting 1450 2021-02-24 2026-11-16
Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) Carfilzomib, Lenalidomide, Dexamethasone - Multiple Myeloma Phase 3 Active not recruiting 250 2019-05-07 2026-03-04
Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma Daratumumab, Velcade, Lenalidomide - Multiple Myeloma Phase 3 Active not recruiting 709 2018-12-14 2026-02-10
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Daratumumab, Bortezomib, Lenalidomide - Multiple Myeloma Phase 3 Completed 395 2018-11-06 2026-11-03
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) Lenalidomide, Bortezomib, Dexamethasone - Multiple Myeloma Phase 3 Active not recruiting 662 2018-10-18 2026-02-03
Rituximab Combining Bortezomib Versus Rituximab in Management of ITP Rituximab, Bortezomib - Immune Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic Phase 3 Unknown 200 2018-03-01 2018-02-23
A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Daratumumab, Velcade, Dexamethasone - Multiple Myeloma Phase 3 Completed 213 2017-11-30 2024-05-29
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) Velcade, Melphalan, Prednisone - Multiple Myeloma Phase 3 Completed 220 2017-11-23 2024-04-25
Bortezomib in Intrahepatic Cholangiocellular Carcinoma Bortezomib - Intrahepatic Cholangiocarcinoma Phase 3 Unknown 50 2017-01-01 2017-11-17
Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma Bortezomib, Dexamethasone - Multiple Myeloma Phase 3 Completed 81 2016-09-27 2019-11-08
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Venetoclax, Bortezomib, Dexamethasone - Relapsed/Refractory Multiple Myeloma Phase 3 Completed 291 2016-07-11 2023-08-22
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma elotuzumab, Lenalidomide, Bortezomib - Multiple Myeloma Phase 3 Completed 564 2015-06-01 2021-09-10
Showing 20 of 48. Sign in to see all of them.
Conditions studied Multiple Myeloma (38) · Immunoglobulin Light-chain Amyloidosis (3) · Immunoproliferative Disorders (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms, Plasma Cell (2) · Paraproteinemias (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Amyloidosis (1) · Blood Protein Disorders (1) · Cardiovascular Diseases (1) · Cholangiocarcinoma (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1)
Sponsors Janssen Research & Development, LLC (7) · National Cancer Institute (NCI) (4) · University of Arkansas (4) · University of Heidelberg Medical Center (3) · Celgene (2) · ECOG-ACRIN Cancer Research Group (2) · SWOG Cancer Research Network (2) · AB Science (1) · AbbVie (1) · Amgen (1) · Asan Medical Center (1) · AstraZeneca (1) · Boston Medical Center (1) · Children's Oncology Group (1) · Fondazione EMN Italy Onlus (1)
Countries United States (28) · Germany (12) · China (11) · Australia (10) · France (10) · Spain (10) · Canada (9) · Italy (9) · Poland (9) · South Korea (9) · Brazil (8) · Japan (8) · United Kingdom (8) · Czechia (7) · Puerto Rico (7)
Top investigators Hartmut Goldschmidt, Prof. Dr. (2) · Amine Bensmaine, MD (1) · Andrzej Jakubowiak, MD (1) · Bart Barlogie, MD, PhD (1) · Bertrand Arnulf, MD (1) · Brian M Durie (1) · David T Teachey (1) · Frits van Rhee, MD, PhD (1) · Gareth Morgan, MD, PhD (1) · Hartmut Goldschmidt, Prof. (1)
Results publications PMID 22689675 , PMID 23897961 , PMID 34289038 , PMID 37990162 , PMID 40501401 , PMID 19104417 , PMID 20807892 , PMID 21098740 , PMID 21146205 , PMID 21228328 , PMID 21791469 , PMID 21951682 , PMID 22498745 , PMID 22674807 , PMID 23305732 , PMID 23603914 , PMID 24055414 , PMID 24386911 , PMID 24449241 , PMID 25015938 , PMID 26056177 , PMID 26671818 , PMID 26771810 , PMID 27557302 , PMID 27829371 , PMID 28017406 , PMID 28419486 , PMID 28586789 , PMID 28642620 , PMID 29231133 , PMID 29567784 , PMID 29675792 , PMID 30610657 , PMID 30626425 , PMID 30773463 , PMID 30987448 , PMID 31097405 , PMID 31138244 , PMID 31221778 , PMID 31221782 , PMID 31248973 , PMID 31836199 , PMID 32029509 , PMID 32819447 , PMID 32866432 , PMID 33006656 , PMID 33129376 , PMID 33151787 , PMID 33242443 , PMID 33357481
NIH funding U10CA180820 (3) , U10CA180886 (3) , U10CA180888 (3) , 2005 (2) , 2014 (2) , 2015 (2) , 2023 (2) , U10CA021115 (2) , U10CA098543 (2) , 2008 (1) , 2018 (1) , U10CA032102 (1) , U24CA196172 (1)